CN112858690B — 一种尿白蛋白/尿肌酐复合质控品及其制备方法
Assigned to Chongqing Zhongmei Zhongyi Bioengineering Co ltd · Expires 2023-11-10 · 3y expired
What this patent protects
本发明提供一种尿白蛋白/尿肌酐复合质控品及其制备方法,由以下组份组成:缓冲液:50~100mmol/L;盐类:5~15g/L;氟芬那酸:5~15g/L;二甲基亚砜:5~15g/L;还原剂:5~15g/L;右旋糖酐:5~15g/L;去泡剂:5~15g/L;增粘剂:0.5‑1g/L;人血清白蛋白:100~200mg/L;肌酐:10~20mmol/L;防腐剂:1g/L;所述质控品的PH为7.2~7.4。本发明可用于评价基于微流控技术的尿白蛋白/尿肌酐检测试剂的准确度,对保证尿白蛋白/尿肌酐检测试剂的实验室检测结果质量,减少误差有重要作用。
USPTO Abstract
本发明提供一种尿白蛋白/尿肌酐复合质控品及其制备方法,由以下组份组成:缓冲液:50~100mmol/L;盐类:5~15g/L;氟芬那酸:5~15g/L;二甲基亚砜:5~15g/L;还原剂:5~15g/L;右旋糖酐:5~15g/L;去泡剂:5~15g/L;增粘剂:0.5‑1g/L;人血清白蛋白:100~200mg/L;肌酐:10~20mmol/L;防腐剂:1g/L;所述质控品的PH为7.2~7.4。本发明可用于评价基于微流控技术的尿白蛋白/尿肌酐检测试剂的准确度,对保证尿白蛋白/尿肌酐检测试剂的实验室检测结果质量,减少误差有重要作用。
Drugs covered by this patent
- Vyndaqel (Tafamidis Meglumine) · Foldrx Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.